Stock Monitor: Achillion Pharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on Esperion Therapeutics, Inc. (NASDAQ: ESPR) all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ESPR as the Company's latest news hit the wire. On May 2, 2018, the Company announced positive top-line results from the second pivotal, Phase-3 study (Study 1/1002-040) the long-term safety study, evaluating the safety, tolerability, and efficacy of bempedoic acid versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) who are inadequately controlled with current lipid-modifying therapies, including maximally tolerated statin therapy. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), which also belongs to the Healthcare sector as the Company Esperion Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Esperion Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Study 1 (1002-040) Met its Primary Endpoint
The 52-week, global, pivotal Phase-3 randomized, double-blind, placebo-controlled, multicenter study enrolled 2,230 patients with ASCVD. The study was conducted at 117 sites in the US, Canada, and Europe. It met the primary endpoint of safety and tolerability and the key efficacy endpoint with on-treatment low-density lipoprotein cholesterol (LDL-C) lowering of an additional 20% at 12 weeks (p<0.001). Patients treated with bempedoic acid also achieved a significant reduction of 22% in high-sensitivity C-reactive protein (hsCRP), an important marker of the underlying inflammation associated with cardiovascular disease.
In this 52-week study, bempedoic acid was observed to be safe and well-tolerated. The occurrence of adverse events (AEs) in bempedoic acid and placebo groups was 78.5% and 78.7%, respectively; or serious adverse events (SAEs) was 14.5% and 14%, respectively. In the study, 0.54% and 0.13% of patients treated with bempedoic acid and placebo group, respectively, had elevations in liver function tests (ALT/AST) of greater than three times the upper limit of normal, repeated and confirmed. The cumulative number of patients now treated with bempedoic acid in Phase-2 and Phase-3 clinical trials total 2,434, of this 0.58 % had elevations in liver function tests greater than three times the upper limit of normal. This rate of elevations in liver function test is consistent with the rate observed in all other previously approved oral LDL-C-lowering therapies. Esperion will present full results from this study at an upcoming medical conference.
Esperion to Submit New Drug Applications to FDA in Q1 2019
Esperion plans to submit New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for bempedoic acid and the bempedoic acid/ ezetimibe combination pill for LDL-C-lowering indications in Q1 2019. Additionally, Esperion plans to submit Marketing Authorization Applications (MAAs) to the European Medicines Agency (EMA) in Q2 2019.
As per mainstream media reports post the announcement of the news, Esperion's shares plummeted in pre-market trading.
About Atherosclerotic Cardiovascular Disease
ASCVD is attributed to the buildup of fat deposits, which essentially clog up the heart's arteries. These deposits are called atheroma or plaque. Plaque is built up over time in the inner lining of the arteries, which limits the blood and oxygen flow and supply to the heart. The disease can occur in any artery, but most commonly it occurs in the aorta, the artery that receives blood directly from the heart. ASCVD can lead to angina pectoris, heart attack, and cardiac arrest.
About Bempedoic Acid
Bempedoic acid is a convenient, complementary, consistent, once-daily, oral LDL-C lowering drug that significantly reduces elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. Bempedoic acid, a first-in-class, non-statin, targeted therapy, works in the liver to block cholesterol biosynthesis. Completed Phase-1 and Phase-2 studies conducted in about 1,300 patients, with more than 800 patients treated with bempedoic acid having produced LDL-C lowering results of up to 30% as monotherapy, 50% in combination with ezetimibe and an incremental 20+% when added to stable statin therapy.
About Esperion Therapeutics, Inc.
Founded in 2008 and headquartered in Ann Arbor, Michigan, Esperion Therapeutics is the Lipid Management company that specializes in developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral therapies for the treatment of patients with elevated LDL-C.
Stock Performance Snapshot
May 3, 2018 - At Thursday's closing bell, Esperion Therapeutics' stock declined 19.28%, ending the trading session at $36.93.
Volume traded for the day: 14.85 million shares, which was above the 3-month average volume of 834.27 thousand shares.
After yesterday's close, Esperion Therapeutics' market cap was at $945.41 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.